Neko Health company profile: valuation, funding & revenue

This Neko Health company profile covers the company's valuation, revenue, funding rounds, investors and history. Neko Health works in healthcare, with a focus on preventive health and full-body scans. It was founded in 2018 and is headquartered in Stockholm, Sweden. Its latest valuation on record is About US$7 billion (reported) (July 2026). Every figure links to a public source, and anything the company hasn't disclosed is marked as such.

Revenue

Funding history

Neko Health timeline

Key dates from the sources on this page, oldest first. Metric snapshots are listed after the funding events.

• 2018 — Neko Health is founded in Stockholm by Hjalmar Nilsonne (CEO) and Daniel Ek.
• Jan 2025 — Series B: US$260M, valuing the company at US$1.8B (post-money). Investors: Lightspeed Venture Partners (lead); General Catalyst, Atomico, Lakestar.
• Jul 2026 — Series C: US$700M, valuing the company at About US$7B (reported). Investors: Lightspeed Venture Partners and O.G. Venture Partners (co-leads); Atomico, General Catalyst, Lakestar.
• July 2026 — Scans performed: More than 100,000 (company-stated).
• July 2026 — Profitability: Company says clinics are profitable at clinic level.

Investors

Neko Health runs clinics where customers get a full-body scan in under an hour, using hundreds of sensors and cameras to check skin, heart, blood and more. Co-founded by Spotify's Daniel Ek, it raised a US$700 million Series C in July 2026 at a valuation reported at about US$7 billion, nearly four times its level 18 months earlier, and is opening its first US clinics in New York. This profile explains how Neko works, its funding, its business model and the criticism it faces.

Neko Health's valuation

Neko's Series C of US$700 million was co-led by Lightspeed Venture Partners and O.G. Venture Partners, with Atomico, General Catalyst and Lakestar, according to Dealroom and HIT Consultant. The valuation of about US$7 billion was reported by outlets citing people familiar with the deal rather than announced by the company, so we label it as reported. The previous round, a US$260 million Series B in January 2025 led by Lightspeed, valued Neko at US$1.8 billion post-money, according to Multiples.

A near-fourfold increase in 18 months is large for a company that sells a consumer health service without insurance reimbursement. Commentators such as Angel Investors Network have questioned the price, while investors point to fast growth, long waiting lists and clinic-level profitability.

How the Neko scan works

A Neko visit centres on a body scan in a purpose-built room. Customers undress to their underwear and stand in a booth surrounded by cameras that map moles and skin marks across the body, while other sensors measure heart rhythm, blood pressure, grip strength and blood flow. A blood test checks markers such as cholesterol, blood sugar and inflammation. The data is processed by Neko's software, and a doctor reviews the results with the customer in the same visit, flagging anything that needs follow-up.

The scan does not use MRI or radiation, which keeps it fast and relatively cheap. In Europe the standard scan has been priced at a few hundred pounds or euros, far less than whole-body MRI services. The idea is to catch early signs of skin cancer, heart disease, diabetes and other conditions, and to track changes over time with repeat scans.

Business model

Neko sells scans directly to consumers, mostly as an out-of-pocket purchase, and is moving toward memberships with repeat scans. It operates its own clinics, designed and built in-house, in Sweden and the UK, and is expanding to the US with New York first. The company says more than 100,000 scans have been performed and that its clinics are profitable at the clinic level, a measure that excludes central costs such as research and expansion. Waiting lists in London and Stockholm have helped it fill clinics quickly.

Founders

Hjalmar Nilsonne, the chief executive, and Daniel Ek, Spotify's co-founder, started Neko in Stockholm in 2018. Ek has funded much of his health and technology investing through his firm Prima Materia. Nilsonne previously founded Watty, an energy technology company. Ek told The New York Times that Neko had entered markets where people queue for scans even though other health services are free, a sign of consumer demand for preventive testing.

Criticism and medical debate

Preventive full-body screening is controversial among doctors. Critics argue that testing healthy people can produce false alarms and "incidental findings" that lead to anxiety, more tests and sometimes unnecessary treatment, and that public health systems may bear the cost of follow-up. Supporters say the scan is non-invasive and focuses on common, treatable conditions where early detection helps. Neko has said it designs its process to reduce unnecessary referrals. Regulators in each market oversee its clinics, and its US launch will bring new rules on medical practice and data.

Competitive landscape

Neko competes with full-body MRI providers such as Prenuvo and Ezra (now part of Function Health), with longevity and testing companies such as Function Health, and with traditional private health checks. Its distinctive features are speed, a lower price than MRI, a consumer-designed experience and its own sensor technology. See our health tech unicorns guide.

Risks

• Clinical value: the long-term health benefit of routine body scans is not yet proven in large trials.
• US execution: opening clinics in a new market with different regulation and costs is hard.
• No insurance coverage: customers pay themselves, which limits the market and makes demand sensitive to the economy.
• Valuation: a reported US$7 billion price sets high expectations for growth.

Questions to ask

• How many scans does Neko perform each month, and how many customers return?
• What share of scans lead to referrals, and how many find serious conditions?
• What does a US scan cost, and how quickly can clinics open?
• When will the company as a whole be profitable?

Timeline in brief

• 2018: founded in Stockholm by Hjalmar Nilsonne and Daniel Ek.
• 2023–2024: first clinics open in Stockholm, then London.
• January 2025: US$260 million Series B at US$1.8 billion.
• July 2026: US$700 million Series C at a reported US$7 billion; US expansion begins in New York.

Neko Health at a glance

Neko Health is a Stockholm preventive health company founded in 2018 by Hjalmar Nilsonne and Daniel Ek. It operates clinics offering a sensor-based full-body scan and blood test with same-day doctor review. It raised a US$260 million Series B at US$1.8 billion in January 2025 and a US$700 million Series C co-led by Lightspeed and O.G. Venture Partners in July 2026 at a reported valuation of about US$7 billion. It has performed more than 100,000 scans and is opening in New York.

What to watch

Watch the New York opening, pricing and demand in the US, published clinical data on outcomes, new European cities and any regulatory challenges. Compare it with other European growth companies in our largest European startups guide.

Takeaways

Neko has turned preventive screening into a fast-growing consumer business and attracted one of Europe's largest health-tech valuations. Whether it justifies that price depends on scaling clinics abroad and showing that its scans improve health, not just awareness.

Sources

Every figure on this page comes from the public sources below. Where sources disagreed, we used the company's own announcement or a primary news report. Private-company data changes; check the date beside each figure.

1. Dealroom
2. HIT Consultant
3. Angel Investors Network
4. Multiples